EW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Edwards Lifesciences Corp (EW) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company demonstrates strong revenue growth and has positive momentum in its TAVR business, the declining net income, EPS, and insider selling are concerning. Additionally, the stock appears overbought technically, and analyst ratings are mostly neutral with limited upside potential. Holding off for a better entry point or more clarity on growth sustainability is advisable.
The stock is showing bullish momentum with MACD above 0 and expanding positively, and moving averages (SMA_5 > SMA_20 > SMA_200) confirming an uptrend. However, RSI at 82.888 indicates the stock is overbought, suggesting a potential pullback. Current price is near resistance levels (R2: 86.996).
Strong Q4 revenue growth (13.26% YoY) driven by TAVR momentum.
Positive sentiment from Piper Sandler and Goldman Sachs, highlighting growth potential and strong business fundamentals.
The Every Heartbeat Matters initiative could enhance the company's brand and long-term growth prospects.
Declining net income (-76.35% YoY) and EPS (-75.38% YoY) in Q4
Insider selling increased by 252.47% over the last month, signaling potential lack of confidence.
Analysts have lowered price targets recently, with many maintaining neutral ratings.
Overbought technical indicators suggest a potential pullback in the short term.
In Q4 2025, revenue increased by 13.26% YoY to $1.57 billion, driven by strong TAVR business momentum. However, net income dropped significantly by 76.35% YoY to $91.2 million, and EPS fell by 75.38% YoY to $0.16. Gross margin also slightly declined to 78.15%.
Analyst sentiment is mixed with several firms lowering price targets recently. UBS, Baird, and Truist have neutral ratings with price targets between $87 and $90. Piper Sandler and Goldman Sachs are more optimistic, with price targets of $100 and $95, respectively. Stifel maintains a buy rating with a $110 target, but overall, the consensus leans towards holding rather than buying.
